Press Release: ViiV Healthcare receives FDA approval for Triumeq(R) (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

Press Release: ViiV Healthcare receives FDA approval for Triumeq(R) (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection ViiV Healthcare receives FDA approval for Triumeq(R) (abacavir, dolutegravir and lamivudine), a new single-pill…

Read more…

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s